Introduction
Gastro-oesophageal reflux disease (GORD) is a chronic and prevalent condition that significantly impacts patients’ quality of life1. Although a wide range of over-the-counter treatments are available, management approaches vary considerably among healthcare professionals (HCPs) globally. Understanding the factors driving these differences is essential to optimise patient outcomes, promote consistent evidence-based care, and minimise inappropriate prescribing and unnecessary costs.
Aims & Methods
This study aimed to explore key perceptual factors influencing HCP decision-making in the management of GORD symptoms across Australia, Thailand, and Italy, and to identify variations in treatment preferences and influential communication channels.
Attributes were derived from qualitative data collected via a 30-minute online survey involving diverse HCP groups, including pharmacists, pharmacy assistants, gastroenterologists, and general practitioners (GPs). A Computer-Assisted Web Interview (CAWI) survey was conducted with 587 participants.
Respondents rated and ranked attributes influencing product recommendations, including speed of symptom relief, tolerability, flavour availability, prevention of reflux, and effectiveness of the product as a monotherapy. Preferences were analysed against perceived product performance, considering country-specific availability. Recommendations for both first-time and repeat patients were assessed.
Results
Rapid symptom relief was consistently perceived as the most important attribute across all HCP groups, with duration of action, tolerability, and prevention of reflux also ranking highly.
Pharmacists and pharmacy assistants rated alginates highly, while GPs and gastroenterologists showed a strong preference for proton pump inhibitors (PPIs).
In Australia and Thailand, alginates were the preferred option for both first-time and repeat patients, scoring highest for tolerability and rapid relief across all HCP groups. In Italy, PPIs were rated highest by GPs across most attributes, except in pregnancy, where alternatives were favoured. This is despite the recent focus in Italy on PPI deprescribing in primary care.
Influences on decision-making varied by country and role. In Australia, pharmacists were most influenced by professional associations (33%), while in Thailand online resources (44%) were dominant, and in Italy scientific meetings were most influential. Pharmacy assistants reported peer interactions (53%) as the main influence in Australia, emails from medical societies in Italy (40%), and pharmaceutical representatives via phone (56%) or face-to-face (43%) in Thailand.
GPs in Australia relied primarily on colleague interactions and continuing professional development (CPD). In Italy, frequent face-to-face engagement with pharmaceutical representatives (over 30 meetings in 3 months) was most influential. In Thailand, international scientific meetings and professional associations were key, despite infrequent attendance.
Conclusion
HCPs consistently prioritise rapid symptom relief when recommending GORD treatments, alongside duration of action, tolerability, and prevention of reflux. Alginates are widely recommended across all countries, particularly in Australia and Thailand. Despite a global trend toward PPI deprescribing, GPs and gastroenterologists continue to favour PPIs for most patients.
References
- Irvine EJ Quality of life assessment in gastro-oesophageal reflux disease Gut 2004;53:iv35-iv39. https://doi.org/10.1136/gut.2003.034314
Disclosure
All authors are employees of Reckitt Benckiser Healthcare Ltd.